Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Result: Among these sites, the rtL180 M came along with rtM204I/V as previous reports, but here we noticed it was not along with rtM204I in genotype B and majority of genotype C.
Result: It demonstrated the previously reported rtL180 M was not the unique compensatory variance.
Discussion: Because the 3D structural modeling has shown that rt180 in the rt173-189 helix is close enough to interact with rtM204 of the YMDD loop (Allen et al.), the rtL180M is ever regarded as the rational expla
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Result: L180M mutation (common to both LAM and
Discussion: It is interesting to note that mutants L180M and M204I that were detected during LAM and ADV breakthrough showed a high prevalence in the LAM-only group (25 and 50%, respectively), followed by a low frequency in the ADV-only group (9.9 and 23%, respectively), whereas they showed a very high frequency in group III in which the patients received ADV after LAM breakthrough (43.75 and 68.75%, respectively).
Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy.
PMID: 27446286
2016
Experimental and therapeutic medicine
Abstract: The turn of secondary protein structure of P gene changed to beta sheet when a rtM204V mutation occurred, and no change of secondary protein structure was associated with the rtL180M mutation.
Abstract: Two patients with rtM204V + rtL180M belonged to genotype C and another patient with rtL180M alone belonged to genotype D.
Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B.
PMID: 27313669
2016
Experimental and therapeutic medicine
Abstract: At the initiation of sequential monotherapy with ADV, LAM-resistant variants (rtM204V/I and rtL180M) were detected in the three patients.
Abstract: During 30-41 months of ADV-ETV combination therapy, viral load reduction was 2.59-3.28 log10 copies/ml; ADV-resistant variants rtA181T/V and rtN236T were undetectable following 11-24 months of combination therapy; and rtL180M and rtM204I/V remained dominant in the viral population.
Abstract: In conclusion, the results of the present study suggested that, in patients with LAM and ADV-resista
Hepatitis B infection in HIV-1-infected patients receiving highly active antiretroviral therapy in Lome, Togo: Prevalence and molecular consequences.
Abstract: The detected resistance mutations were rtL180M (14/15 patients) and rtM204V/I (15/15).
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.
PMID: 27079793
2016
Annals of clinical microbiology and antimicrobials
Abstract: Specifically, we found one rtM204I+rtL180 M+rtM250 V+rtA181 V clone among 23 clones from patient 1 (4.35 %), one rtM204 V+vrtL180 M +rtM250 V+rtA181 V clone among 24 clones from patient 2 (4.17 %), and 2 clones harboring rtM204 V+rtL180 M+rtM250 V+rt
Overt and occult hepatitis B virus infection among treatment-naive HIV-infected patients in Brazil.
Abstract: One patient had the M204I and L180M drug-resistance mutations (polymerase).
Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2.
PMID: 27006281
2016
Infection, genetics and evolution
Abstract: In addition, two patients harboring drug resistance mutations rtL80V+rtM204I and rtL180M+rtM204V were found.
[Drug-resistant mutations in hepatitis B virus found in chronic HBV carriers using PCR sequencing technology].
Abstract: Each of the NAs had dominant drug-resistant mutational profiles, with rtM204I+rtL180M+-rtL80I (30.9%) for LAM, rtA181T/N (21.3%), rtS213T/N (21.3%) and rtV214A (21.3%) for ADV, rtl180M (48%) for ETV, rtM204I for LdT, and rtA194T for tenofovir disoproxil fumarate (TDF).
HBV mutation literature information.
PMID: 
2016
Oncotarget
Browser Board
Co-occurred Entities
Filtrator
ViMRT